ST
RGLS

Spot Trading’s Regulus Therapeutics RGLS Stock Holding History

Spot Trading’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-167
Closed -$321K – 4263
2014
Q4 		$321K Buy
+167
New +$297K ﹤0.01% 2646

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Spot Trading's RGLS Position: Q1 2015 in Review

Spot Trading sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 54 shares — an estimated $105K sold.

Spot Trading first reported a position in RGLS in Q4 2014 and held it in 1 quarter. The position peaked at $105K in Q4 2014. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

  • Spot Trading reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Spot Trading sold 54 Regulus Therapeutics shares in Q1 2015, an estimated $105K.
  • Spot Trading first reported a position in Regulus Therapeutics in Q4 2014 and held it in 1 quarter.
  • Spot Trading's Regulus Therapeutics position peaked at $105K in Q4 2014.
  • 88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on Spot Trading's 13F filing for Q1 2015, filed 12 May 2015.